NVS
Price
$112.27
Change
+$1.50 (+1.35%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
197.93B
26 days until earnings call
RHHBY
Price
$39.37
Change
-$1.71 (-4.16%)
Updated
Apr 2 closing price
Capitalization
250.69B
21 days until earnings call
Ad is loading...

NVS vs RHHBY

Header iconNVS vs RHHBY Comparison
Open Charts NVS vs RHHBYBanner chart's image
Novartis AG
Price$112.27
Change+$1.50 (+1.35%)
Volume$31.79K
Capitalization197.93B
Roche Holding
Price$39.37
Change-$1.71 (-4.16%)
Volume$2.99M
Capitalization250.69B
NVS vs RHHBY Comparison Chart
Loading...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RHHBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NVS vs. RHHBY commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVS is a Hold and RHHBY is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (NVS: $110.77 vs. RHHBY: $39.37)
Brand notoriety: NVS and RHHBY are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: NVS: 114% vs. RHHBY: 87%
Market capitalization -- NVS: $197.93B vs. RHHBY: $250.69B
NVS [@Pharmaceuticals: Major] is valued at $197.93B. RHHBY’s [@Pharmaceuticals: Major] market capitalization is $250.69B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVS’s FA Score shows that 2 FA rating(s) are green whileRHHBY’s FA Score has 2 green FA rating(s).

  • NVS’s FA Score: 2 green, 3 red.
  • RHHBY’s FA Score: 2 green, 3 red.
According to our system of comparison, NVS is a better buy in the long-term than RHHBY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVS’s TA Score shows that 3 TA indicator(s) are bullish while RHHBY’s TA Score has 4 bullish TA indicator(s).

  • NVS’s TA Score: 3 bullish, 6 bearish.
  • RHHBY’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, RHHBY is a better buy in the short-term than NVS.

Price Growth

NVS (@Pharmaceuticals: Major) experienced а +0.57% price change this week, while RHHBY (@Pharmaceuticals: Major) price change was -4.58% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -2.14%. For the same industry, the average monthly price growth was -3.59%, and the average quarterly price growth was -8.49%.

Reported Earning Dates

NVS is expected to report earnings on Apr 29, 2025.

RHHBY is expected to report earnings on Apr 24, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-2.14% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RHHBY($251B) has a higher market cap than NVS($198B). NVS has higher P/E ratio than RHHBY: NVS (23.38) vs RHHBY (19.46). NVS YTD gains are higher at: 17.930 vs. RHHBY (16.626). RHHBY (19.1B) and NVS (18.3B) have comparable annual earnings (EBITDA) . NVS has more cash in the bank: 14B vs. RHHBY (7.51B). RHHBY (25.4B) and NVS (26.3B) have identical debt. RHHBY has higher revenues than NVS: RHHBY (60B) vs NVS (46.7B).
NVSRHHBYNVS / RHHBY
Capitalization198B251B79%
EBITDA18.3B19.1B96%
Gain YTD17.93016.626108%
P/E Ratio23.3819.46120%
Revenue46.7B60B78%
Total Cash14B7.51B186%
Total Debt26.3B25.4B104%
FUNDAMENTALS RATINGS
NVS vs RHHBY: Fundamental Ratings
NVS
RHHBY
OUTLOOK RATING
1..100
8283
VALUATION
overvalued / fair valued / undervalued
1..100
15
Undervalued
14
Undervalued
PROFIT vs RISK RATING
1..100
1568
SMR RATING
1..100
3799
PRICE GROWTH RATING
1..100
4442
P/E GROWTH RATING
1..100
7010
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RHHBY's Valuation (14) in the null industry is in the same range as NVS (15) in the Pharmaceuticals Major industry. This means that RHHBY’s stock grew similarly to NVS’s over the last 12 months.

NVS's Profit vs Risk Rating (15) in the Pharmaceuticals Major industry is somewhat better than the same rating for RHHBY (68) in the null industry. This means that NVS’s stock grew somewhat faster than RHHBY’s over the last 12 months.

NVS's SMR Rating (37) in the Pharmaceuticals Major industry is somewhat better than the same rating for RHHBY (99) in the null industry. This means that NVS’s stock grew somewhat faster than RHHBY’s over the last 12 months.

RHHBY's Price Growth Rating (42) in the null industry is in the same range as NVS (44) in the Pharmaceuticals Major industry. This means that RHHBY’s stock grew similarly to NVS’s over the last 12 months.

RHHBY's P/E Growth Rating (10) in the null industry is somewhat better than the same rating for NVS (70) in the Pharmaceuticals Major industry. This means that RHHBY’s stock grew somewhat faster than NVS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NVSRHHBY
RSI
ODDS (%)
Bearish Trend 2 days ago
39%
Bearish Trend 2 days ago
72%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
44%
Bullish Trend 2 days ago
58%
Momentum
ODDS (%)
Bearish Trend 2 days ago
44%
Bearish Trend 2 days ago
43%
MACD
ODDS (%)
Bearish Trend 2 days ago
44%
Bearish Trend 2 days ago
55%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
49%
Bearish Trend 2 days ago
45%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
44%
Bearish Trend 2 days ago
49%
Advances
ODDS (%)
Bullish Trend 7 days ago
47%
Bullish Trend 14 days ago
50%
Declines
ODDS (%)
Bearish Trend 3 days ago
43%
Bearish Trend 2 days ago
44%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
52%
Bullish Trend 2 days ago
59%
Aroon
ODDS (%)
Bullish Trend 2 days ago
36%
Bullish Trend 2 days ago
41%
View a ticker or compare two or three
Ad is loading...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RHHBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FSRKX8.74N/A
N/A
Fidelity Strategic Real Return K6
KCEIX11.98N/A
N/A
Knights of Columbus Long/Short Eq I
CGLAX16.14N/A
N/A
Calvert Global Equity Fund Class A
HHHYX17.30N/A
N/A
Hartford Schroders Emerging Mkts Eq Y
VEIGX34.71N/A
N/A
Vanguard Global ESG Select Stk Investor

NVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVS
1D Price
Change %
NVS100%
+1.06%
GSK - NVS
49%
Loosely correlated
-0.61%
AZN - NVS
48%
Loosely correlated
-0.52%
JNJ - NVS
40%
Loosely correlated
+1.38%
PFE - NVS
39%
Loosely correlated
+0.65%
SNY - NVS
38%
Loosely correlated
-0.72%
More

RHHBY and

Correlation & Price change

A.I.dvisor indicates that over the last year, RHHBY has been loosely correlated with RHHVF. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if RHHBY jumps, then RHHVF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RHHBY
1D Price
Change %
RHHBY100%
-4.16%
RHHVF - RHHBY
65%
Loosely correlated
-0.18%
NVS - RHHBY
37%
Loosely correlated
+1.06%
JNJ - RHHBY
37%
Loosely correlated
+1.38%
RHHBF - RHHBY
32%
Poorly correlated
-6.61%
BMY - RHHBY
28%
Poorly correlated
+0.08%
More